Browse FER1L6

Summary
SymbolFER1L6
Namefer-1-like family member 6
Aliases C8ORFK23; fer-1-like 6 (C. elegans); fer-1-like 6; Fer-1-like protein 6
Chromosomal Location8q24.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass membrane protein
Domain PF00168 C2 domain
PF08150 FerB (NUC096) domain
PF08151 FerI (NUC094) domain
PF16165 Ferlin C-terminus
Function

-

> Gene Ontology
 
Biological Process -
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolFER1L6
Namefer-1-like family member 6
Aliases C8ORFK23; fer-1-like 6 (C. elegans); fer-1-like 6; Fer-1-like protein 6
Chromosomal Location8q24.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FER1L6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolFER1L6
Namefer-1-like family member 6
Aliases C8ORFK23; fer-1-like 6 (C. elegans); fer-1-like 6; Fer-1-like protein 6
Chromosomal Location8q24.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FER1L6 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFER1L6
Namefer-1-like family member 6
Aliases C8ORFK23; fer-1-like 6 (C. elegans); fer-1-like 6; Fer-1-like protein 6
Chromosomal Location8q24.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FER1L6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1790.239
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0860.866
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2460.548
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1020.88
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.7880.631
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.2150.493
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.6590.484
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.8230.598
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5250.751
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0370.931
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0350.956
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.7720.0227
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FER1L6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.35.98.40.576
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1032033.3-13.31
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.815.1-0.31
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.818.6-3.80.767
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211723.823.50.31
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8637.5037.50.209
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.436.4-210.357
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.514.8-4.30.709
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.623.1-9.50.648
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFER1L6
Namefer-1-like family member 6
Aliases C8ORFK23; fer-1-like 6 (C. elegans); fer-1-like 6; Fer-1-like protein 6
Chromosomal Location8q24.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FER1L6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFER1L6
Namefer-1-like family member 6
Aliases C8ORFK23; fer-1-like 6 (C. elegans); fer-1-like 6; Fer-1-like protein 6
Chromosomal Location8q24.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FER1L6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FER1L6.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFER1L6
Namefer-1-like family member 6
Aliases C8ORFK23; fer-1-like 6 (C. elegans); fer-1-like 6; Fer-1-like protein 6
Chromosomal Location8q24.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FER1L6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFER1L6
Namefer-1-like family member 6
Aliases C8ORFK23; fer-1-like 6 (C. elegans); fer-1-like 6; Fer-1-like protein 6
Chromosomal Location8q24.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FER1L6 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFER1L6
Namefer-1-like family member 6
Aliases C8ORFK23; fer-1-like 6 (C. elegans); fer-1-like 6; Fer-1-like protein 6
Chromosomal Location8q24.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FER1L6 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFER1L6
Namefer-1-like family member 6
Aliases C8ORFK23; fer-1-like 6 (C. elegans); fer-1-like 6; Fer-1-like protein 6
Chromosomal Location8q24.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FER1L6 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.